Most cited papers from BioMarin (Netherlands)

BioMarin (Netherlands)

What are the most cited papers from BioMarin (Netherlands)?

The most cited paper from BioMarin (Netherlands) is "Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib" (Lisa A. Carey, Donald A. Berry, Constance Cirrincione et al., 2015), with 442 citations. Next come "Benchmarking of commercially available CHO cell culture media for antibody production" (146) and "Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy" (136).

Published TypeFieldAccessCitations

Showing 36 of 36 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib Lisa A. Carey, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology Open access	2 Nov 2015	442
2	Benchmarking of commercially available CHO cell culture media for antibody production David Reinhart, Lukas Damjanovic, Christian Kaisermayer et al. · Applied Microbiology and Biotechnology Open access	5 Apr 2015	146
3	Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy Chantal Beekman, Anneke A. M. Janson, Aabed Baghat et al. · PLoS ONE Open access	11 Apr 2018	136
4	Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study Nathalie Goemans, M. Tulinius, M. van den Hauwe et al. · PLoS ONE Open access	2 Sep 2016	94
5	The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain Nicole A. Datson, Anchel González‐Barriga, Eleni Kourkouta et al. · PLoS ONE Open access	9 Feb 2017	74
6	Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide Eleni Kourkouta, Rudie Weij, Anchel González‐Barriga et al. · Molecular Therapy — Nucleic Acids Open access	20 Jul 2019	65
7	Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology Annemieke M Aartsma-Rus, on behalf of the workshop participants, Jennifer Elizabeth Morgan et al. · Journal of Neuromuscular Diseases Open access	4 Jan 2019	57
8	Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy Ruurd C. Verheul, J.C.T. van Deutekom, Nicole A. Datson · PLoS ONE Open access	9 Sep 2016	39
9	Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy Craig M. McDonald, Brenda L. Y. Wong, Kevin M. Flanigan et al. · Annals of Clinical and Translational Neurology Open access	11 Jul 2018	37
10	Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne Afrodite Lourbakos et al. · Scientific Reports Open access	14 Dec 2017	31
11	Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy Silvana M.G. Jirka, Peter A.C. ’t Hoen, Valeriano Diaz Parillas et al. · Molecular Therapy Open access	13 Oct 2017	31
12	Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model Alper Yavas, Rudie Weij, Maaike van Putten et al. · PLoS ONE Open access	23 Dec 2020	30
13	Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro Anchel González‐Barriga, Bram Nillessen, Julia Kranzen et al. · Nucleic Acid Therapeutics Open access	4 Apr 2017	30
14	The Pharmacokinetics of 2′- O -Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy Sieto Bosgra, Jessica A. Sipkens, Sjef de Kimpe et al. · Nucleic Acid Therapeutics	20 Aug 2019	29
15	A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures Monika Hiller, Maria Sofia Falzarano, Iker García et al. · PLoS ONE Open access	2 Oct 2018	28
16	Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay Zaïda Koeks, Annika Janson, Chantal Beekman et al. · Scientific Reports Open access	15 Mar 2021	24
17	Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption Manoe Jacoba Janssen, Tom T.G. Nieskens, Tessa A. M. Steevels et al. · Molecular Therapy — Nucleic Acids Open access	6 Sep 2019	23
18	Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a 26Al Microtracer Approach Rianne de Ligt, Esther van Duijn, Dimitri Grossouw et al. · Clinical and Translational Science Open access	27 Jul 2018	23
19	Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy Silvana M.G. Jirka, Christa L. Tanganyika-de Winter, Joke W. Boertje-van der Meulen et al. · Molecular Therapy — Nucleic Acids Open access	2015	23
20	The licorice pentacyclic triterpenoid component 18β-glycyrrhetinic acid enhances the activity of antibiotics against strains of methicillin-resistant Staphylococcus aureus Anna de Breij, T. G. Karnaoukh, Jasmijn A. Schrumpf et al. · European Journal of Clinical Microbiology & Infectious Diseases	15 Jan 2016	21
21	Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy Judith Van Deutekom et al. · Nucleic Acid Therapeutics Open access	10 Apr 2023	20
22	Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids Nathalie Goemans, M. Tulinius, Anna‐Karin Kroksmark et al. · Neuromuscular Disorders Open access	25 Nov 2016	20
23	Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay Marilena Colaianna, Sten Ilmjärv, Hedi Peterson et al. · Archives of Toxicology Open access	25 Mar 2016	16
24	Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop Jeffrey S. Barrett, Christina M. Bucci-Rechtweg, S. Y. Amy Cheung et al. · Clinical Pharmacology & Therapeutics Open access	4 Feb 2020	13
25	Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice Nicole A. Datson, Suzanne Bijl, Anneke A. M. Janson et al. · Nucleic Acid Therapeutics Open access	10 Dec 2019	11
26	Nonclinical Exon Skipping Studies with 2′- O -Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results Maaike van Putten, C. Tanganyika-de Winter, Sieto Bosgra et al. · Nucleic Acid Therapeutics Open access	23 Jan 2019	9
27	Persistent Hypersomnolence Following Clobazam in a Child With Epilepsy and Undiagnosed CYP2C19 Polymorphism Katherine E. Hamilton, Chasity M. Shelton, James W. Wheless et al. · The Journal of Pediatric Pharmacology and Therapeutics Open access	2020	7
28	Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy Evita van de Steeg, Tilman Läppchen, Begoña Aguilera et al. · Nucleic Acid Therapeutics	18 Apr 2017	5
29	Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice Monika Hiller, Pietro Spitali, Nicole A. Datson et al. · Methods in molecular biology Book chapter	2018	4
30	How Do Individuals Value Worse-Than-Dead EQ-5D-5L Health States in Composite Time Trade-Off Tasks? A Qualitative Study Meixia Liao, Zhihao Yang, Milad Karimi et al. · Value in Health Open access	6 Feb 2025	1
31	Minimum dietary level and mix ratio of krill meal and fish meal to elicit feed intake and growth performance in juvenile Penaeus vannamei Alberto Jorge Pinto Nunes, Jordana Sampaio Leite, Caio Gabriel Dantas Gomes et al. · Research Square PreprintOpen access	12 Feb 2024	0
32	L2 The expanded cag repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the R6/2 and Q175 HD mouse brain Anchel González‐Barriga, Eleni Kourkouta, Outi Kontkanen et al. · Journal of Neurology Neurosurgery & Psychiatry	Sep 2016	0
33	Comparing biomarker expression between sub-populations of Duchenne muscular dystrophy patients, measured using immunostaining in muscle biopsies Karin Boekhoorn, Chantal Beekman, Simone van Wijngaarden et al. · Neuromuscular Disorders	9 Sep 2016	0
34	Effect of different dosing regimens of exon skipping antisense oligonucleotides on functional outcome in the mdx mouse model of Duchenne muscular dystrophy Nicole A. Datson, Rudie Weij, Suzanne Bijl et al. · Neuromuscular Disorders	10 Sep 2015	0
35	Longitudinal quantitative muscle MRI in 5 Duchenne boys on and off drisapersen treatment Melissa T. Hooijmans, Beatrijs H. A. Wokke, Natalie Goemans et al. · Neuromuscular Disorders	10 Sep 2015	0
36	Development of a patient-reported outcome measure for arm and hand function in Duchenne muscular dystrophy (UL-PROM DMD) Katrijn Klingels, Anna G Mayhew, Elena Stacy Mazzone et al. · Neuromuscular Disorders	10 Sep 2015	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.